FDA Generic-Drug Leader Steps Down Amid Agency Changes

Law360, New York (March 14, 2013, 6:10 PM EDT) -- The head of the U.S. Food and Drug Administration's generic-drug arm will resign Friday after less than a year in the position, citing an upcoming restructuring of the agency that he said would compromise his ability to achieve his original goals.

In an email to staffers Wednesday, Gregory Geba, the director of the agency's Office of Generic Drugs, pointed to the shift of the office's chemistry divisions into a new Office of Pharmaceutical Quality as one of the main reasons for his departure.

Geba said the...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.